Xellia Pharmaceuticals Expands Anti-Infective Product Manufacturing
Xellia Pharmaceuticals invests US$25 million in its Copenhagen, Denmark site to expand sterile manufacturing of products for treating antimicrobial resistant infections.
Xellia Pharmaceuticals held a ground-breaking ceremony for a new US$25-million expansion at its Copenhagen, Denmark site, the company announced in a Oct. 11, 2017 press release. The company has begun construction of a multi-story building that will house sterile manufacturing equipment and containment solutions in a purpose-built environment for manufacturing products for treating antimicrobial resistant infections.
This site also houses Xellia’s headquarters and is the company’s largest product manufacturing plant. It is responsible for manufacturing, stability testing, and packaging of both sterile APIs and finished dosage forms for anti-infectives such as vancomycin and colistimethate sodium. This upgrade in facilities will ensure that the company is able to continue to provide a reliable supply of injectable anti-infective critical care medicines.
Source: Xellia
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
